Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Storz

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Mabs|October 16, 2015
Intellectual property issues of immune checkpoint inhibitorsUlrich Storz
Mabs|August 21, 2015
Antibody-drug conjugates: Intellectual property considerationsUlrich Storz
Mabs|May 29, 2014
Rituximab: how approval history is reflected by a corresponding patent filing strategyUlrich Storz
Journal of Biotechnology|July 14, 2025
The CRISPR Cas patent files, part 3: Prime Editing and integrase-based variantsUlrich Storz
Mabs|April 16, 2011
Intellectual property protection: strategies for antibody inventionsUlrich Storz
Mabs|November 30, 2011
International intellectual property strategies for therapeutic antibodiesUlrich Storz
Human Antibodies|October 30, 2016
Of patents and patent disputes: The TNFα patent files. Part 1: HumiraUlrich Storz
Mabs|April 27, 2016
Extending the market exclusivity of therapeutic antibodies through dosage patentsUlrich Storz
Human Antibodies|April 19, 2024
The rebirth of epitope-based patent claimsUlrich Storz
Regenerative Medicine|December 16, 2016
Patent eligibility of stem cells in Europe: where do we stand after 8 years of case law?Ulrich Storz, Timo Faltus
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Mabs|October 16, 2015
Intellectual property issues of immune checkpoint inhibitorsUlrich Storz
Mabs|August 21, 2015
Antibody-drug conjugates: Intellectual property considerationsUlrich Storz
Mabs|May 29, 2014
Rituximab: how approval history is reflected by a corresponding patent filing strategyUlrich Storz
Journal of Biotechnology|July 14, 2025
The CRISPR Cas patent files, part 3: Prime Editing and integrase-based variantsUlrich Storz
Mabs|April 16, 2011
Intellectual property protection: strategies for antibody inventionsUlrich Storz
Mabs|November 30, 2011
International intellectual property strategies for therapeutic antibodiesUlrich Storz
Human Antibodies|October 30, 2016
Of patents and patent disputes: The TNFα patent files. Part 1: HumiraUlrich Storz
Mabs|April 27, 2016
Extending the market exclusivity of therapeutic antibodies through dosage patentsUlrich Storz
Human Antibodies|April 19, 2024
The rebirth of epitope-based patent claimsUlrich Storz
Regenerative Medicine|December 16, 2016
Patent eligibility of stem cells in Europe: where do we stand after 8 years of case law?Ulrich Storz, Timo Faltus
Pageof 3